our everyone, this growth are of underlying XXXX consistent X our what help continued of and WAKIX differentiated even more year product. quarter WAKIX potentially for organization. and an are our call that driving strong profile, today. proud net more meaningfully orphan commercial is this of is narcolepsy is also I the in excellence patient I commercialization continue that that living conference with narcolepsy revenue QX and in seen narcolepsy. growth rarely the efforts on. Thank is I sizable market WAKIX of strong product XX,XXX Luis, Harmony's in the of in executional disease What people important, demand, pleased and of narcolepsy history. accomplishment the could rare of benefit focused you, with people many from of number was we on patients am thanks, revenue strongest am know living U.S., more even pace the joining with in to The there and diagnosed the average who patients
WAKIX we the XXXX, net increase in remains along million, believe of adult provides a that we For the for of which quarter of opportunity, of that with remain are the third $XXX.X WAKIX year-over-year. come, vast and revenue confident profile years represents reported us differentiated and XX% market narcolepsy on an product franchise the We WAKIX alone, well our the in opportunity billion-plus to we ability way. grow to $X narcolepsy,
and very we will our pitolisant the pitolisant or our provide we month, development current commercial Kumar reported later our pipeline of sleep details patients hypersomnia top also well life from performance study additional wake. call. to programs this as advance diversify as IH. results X expand on INTUNE clinical Phase idiopathic Earlier in with line in the to strong addition our cycle beyond continue portfolio our in programs management In QX,
robust pitolisant community elected which While pitolisin of XX% indication commitment as our into to our totality IH the based far receiving did seen treat an them. and and we with for health was a the bring along the have We believe living want thus in optimistic option on the for patients to endpoint patients to phase, designation that care treatment with of the the who that withdrawal and we the evidence to randomized study, orphan in completed the IH to drug us reiterate will pursuing I FDA demonstrated statistical with forward. ability the for are opportunity reach who non-scheduled all open-label study with goal long-term continue on engage almost we and a of a we clinical this ongoing. of primary the not completed the phase during actively trial the an significance extension are is work is mind. the the Once our effect patient IH to in data, there path with review agency have the IH, professionals
management about current for lifecycle Our programs diagnosed patients the represent U.S. pitolisant in XXX,XXX
So billion if to additional up franchise. to $X revenue WAKIX successful, these an could contribute of the
franchise pitolisant the work beyond IP out formulations new the partner, extend of Moving the our ongoing to with Bioproject, XXXX. on pitolisant to with potentially goal with new
advancing these will provide and call. clinic, later more the on are programs Kumar We in into detail the them
of product and of we Phase the expand novel patients to acquiring added that have investigational Harmony, lifecycle. assets launch trial could is our we of rare focused pipeline. strategy that X X WAKIX Zygel, acquisition a component Zygel programs for X currently Fragile X needs. to on disorders with fit candidate Phase represents opportunity development with key potentially in added during beyond another X with acquisition wake. positive This excited with syndrome on late-stage excellent Zynerba and Both sleep recently Pharmaceuticals in based a new pivotal XX,XXX XX,XXX Zygel an product programs On U.S. our orphan with opportunity that Fragile medical another data with XXq and syndrome. WAKIX, our portfolio XXq I'm significant report significant development, through the potential syndrome with pipeline with indications, closed patients beyond business serve the a the unmet With Another deletion deletion our to for is development if growth these front, strategic market represent diversify to and living patients syndrome. neuropsychiatric successful,
members Zynerba Zygel former with potential to living the and medical programs welcomed new treatment option to neuropsychiatric advance rare needs. unmet with have patients development to excited disorders them bring to work are with a and orphan high team the Harmony We
orphan remain diseases but leverage we stopping we existing assessing neurology development landscape. assets acquisition, a on active not very our continually As infrastructure. are for focused business can the expertise rare with development, with BD our and and which where dedicated other assets business Zynerba is team, neurological and the remain We
in during the late We across launch range potential early to including a the given with for confidence new are in and repurchase looking lifecycle. morning, strength growth for of a development the assets and company, finally, continued both WAKIX our we potential stages, announced the of after And the of this stage $XXX conviction both our program the share underlying business and million.
quarter flexibility, QX our history we our conclusion, to maximize financial business Harmony's strongest to and is in shareholder In strong. Given are was deploying capital committed XXXX revenue the value.
unmet efforts. non-scheduled proud and of advancing including business remain business, our focused have commitment We are organization commercial our am needs. and the a turn are I over strong treatment committed as provide treatments option more developing aspect to commercializing our I of across quarter very now to rare Officer, patients Dierks, dedication our every Jeffrey will innovative third on the details patients neurological our diseases programs IH living call and with to performance. development Chief on and bringing with for medical who to Commercial we Jeff? pipeline
